Cargando…

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

Multiple myeloma (MM) is a hematological disease characterized by the proliferation and accumulation of malignant plasmacells (PCs) in the bone marrow (BM). Despite widespread use of high-dose chemotherapy in combination with autologous stem cell transplantation (ASCT) and the introduction of novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zannetti, Beatrice Anna, Faini, Angelo Corso, Massari, Evita, Geuna, Massimo, Maffini, Enrico, Poletti, Giovanni, Cerchione, Claudio, Martinelli, Giovanni, Malavasi, Fabio, Lanza, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764337/ https://www.ncbi.nlm.nih.gov/pubmed/33322499 http://dx.doi.org/10.3390/cells9122666

Ejemplares similares

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
por: Lanza, Francesco, et al.
Publicado: (2020)

The Circular Life of Human CD38: From Basic Science to Clinics and Back
por: Horenstein, Alberto L., et al.
Publicado: (2020)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes
por: Deaglio, Silvia, et al.
Publicado: (2006)

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies
por: Morandi, Fabio, et al.
Publicado: (2019)

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
por: Horenstein, Alberto L., et al.
Publicado: (2019)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
por: Costa, Federica, et al.
Publicado: (2021)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque
por: Ferrero, Enza, et al.
Publicado: (2004)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
por: Horenstein, Alberto L, et al.
Publicado: (2013)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFNγ Cytokines and Proliferation
por: Fedele, Giorgio, et al.
Publicado: (2013)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
por: Leleu, Xavier, et al.
Publicado: (2022)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+ or CD38+ cells
por: Pessler, Frank, et al.
Publicado: (2014)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD(+)-Lowering Agents
por: Becherini, Pamela, et al.
Publicado: (2023)

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma
por: Broijl, Annemiek, et al.
Publicado: (2021)

The role of CD38 in HIV infection
por: Lu, Liqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_37e0qh7f349btd8ul9chs80tp5